Prostate Cancer Reports

Volume 6 Number 12
December 2018


Home > Prostate Cancer Reports > Volume 6, Year 2018 > Number 12, December



CONTENTS


DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
PROGNOSIS
TREATMENT





DIAGNOSIS

.

Antunes HP, Parada B, Carvalho J, Eliseu M, Jarimba R, Oliveira R, Tavares-da-Silva E, Figueiredo A.
Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
Arch Ital Urol Androl. 2018 Sep 30;90(3):191-194. doi: 10.4081/aiua.2018.3.191.
Source | Full text | Similar articles



.

Bianchi G, Sighinolfi MC, Rocco B.
Magnetic Resonance Imaging-Based Prediction of Prostate Cancer Risk.
JAMA Oncol. 2018 Nov 1;4(11):1624-1625. doi: 10.1001/jamaoncol.2018.4221.
Comment on: Mehralivand S et al, A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.
Source | Full text | Similar articles



.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
Eur J Nucl Med Mol Imaging. 2018 Oct 22. doi: 10.1007/s00259-018-4189-7. [Epub ahead of print]
Source | Full text | Similar articles



.

Cengiz A, Göksel S, Yürekli Y.
Diagnostic Value of 18F-FDG PET/CT in Patients with Carcinoma of Unknown Primary
Mol Imaging Radionucl Ther. 2018 Oct 9;27(3):126-132. doi: 10.4274/mirt.64426.
Source | Full text | Similar articles



.

Mehralivand S, Shih J, Turkbey B.
Magnetic Resonance Imaging-Based Prediction of Prostate Cancer Risk-Reply.
JAMA Oncol. 2018 Nov 1;4(11):1625. doi: 10.1001/jamaoncol.2018.4234. Epub 2018 Sep 20.
Source | Full text | Similar articles



.

Mehralivand S, Shih JH, Rais-Bahrami S, Oto A, Bednarova S, Nix JW, Thomas JV, Gordetsky JB, Gaur S, Harmon SA, Siddiqui MM, Merino MJ, Parnes HL, Wood BJ, Pinto PA, Choyke PL, Turkbey B.
A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.
JAMA Oncol. 2018 May 1;4(5):678-685. doi: 10.1001/jamaoncol.2017.5667.
Source | Abstract | Similar articles



.

Pickersgill NA, Vetter JM, Andriole GL, Shetty AS, Fowler KJ, Mintz AJ, Siegel CL, Kim EH.
Accuracy and Variability of Prostate Multiparametric Magnetic Resonance Imaging Interpretation Using the Prostate Imaging Reporting and Data System: A Blinded Comparison of Radiologists.
Eur Urol Focus. 2018 Oct 13. pii: S2405-4569(18)30301-8. doi: 10.1016/j.euf.2018.10.008. [Epub ahead of print]
Source | Full text | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION

.

Rangul V, Sund ER, Mork PJ, Røe OD, Bauman A.
The associations of sitting time and physical activity on total and site-specific cancer incidence: Results from the HUNT study, Norway.
PLoS One. 2018 Oct 23;13(10):e0206015. doi: 10.1371/journal.pone.0206015. eCollection 2018.
Source | Full text | Similar articles



.

Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ.
Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.
Clin Genitourin Cancer. 2018 Oct 4. pii: S1558-7673(18)30491-9. doi: 10.1016/j.clgc.2018.09.022. [Epub ahead of print]
Source | Full text | Similar articles



PROGNOSIS

.

Evren I, Hacıislamoğlu A, Ekşi M, Yavuzsan AH, Baytekin F, Çolakoğlu Y, Canoğlu D, Tugcu V.
The impact of single positive surgical margin features on biochemical recurrence after robotic radical prostatectomy.
Int Braz J Urol. 2018 Sep 10;44. doi: 10.1590/S1677-5538.IBJU.2017.0702. [Epub ahead of print]
Source | Full text | Similar articles



.

Lee KS, Koo KC, Chung BH.
Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy.
World J Urol. 2018 Oct 22. doi: 10.1007/s00345-018-2531-0. [Epub ahead of print]
Source | Full text | Similar articles



.

Penney KL, Loda M, Stampfer MJ.
Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
Eur Urol. 2018 Oct 12. pii: S0302-2838(18)30744-9. doi: 10.1016/j.eururo.2018.10.004. [Epub ahead of print]
Source | Full text | Similar articles



.

Poelaert F, Schatteman P, Lumen N.
Editorial Comment to ‘Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital’.
Int J Urol. 2018 Oct 22. doi: 10.1111/iju.13837. [Epub ahead of print]
Source | Full text | Similar articles



.

Rantaniemi L, Tammela TLJ, Kujala P, Murtola TJ.
Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.
Scand J Urol. 2018 Oct 26:1-8. doi: 10.1080/21681805.2018.1492967. [Epub ahead of print]
Source | Full text | Similar articles



.

Taneja SS.
Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate Cancer.
J Urol. 2018 Nov;200(5):945-946. doi: 10.1016/j.juro.2018.08.027. Epub 2018 Aug 16.
Source | Full text | Similar articles



.

Vickers AJ, Lilja H, Assel M.
Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30743-7. doi: 10.1016/j.eururo.2018.10.003. [Epub ahead of print]
Source | Full text | Similar articles



TREATMENT

.

Boeri L, Sharma V, Karnes RJ.
Radiotherapy for newly diagnosed oligometastatic prostate cancer.
Lancet. 2018 Oct 21. pii: S0140-6736(18)32598-4. doi: 10.1016/S0140-6736(18)32598-4. [Epub ahead of print]
Comment on: Parker CC et al, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. [Lancet. 2018 Oct 21].
Source | Full text | Similar articles



.

Marret G, Doucet L, Hennequin C, Fizazi K, Culine S.
Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients.
Cancer Treat Res Commun. 2018;17:37-42. doi: 10.1016/j.ctarc.2018.10.001. Epub 2018 Oct 16.
Source | Full text | Similar articles



.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet. 2018 Oct 21. pii: S0140-6736(18)32486-3. doi: 10.1016/S0140-6736(18)32486-3. [Epub ahead of print]
Source | Full text | Similar articles



.

Patard PM, Roumiguié M, Prudhomme T, Doumerc N, Thoulouzan M, Gamé X, de la Taille A, Rischmann P, Soulié M, Salomon L, Beauval JB.
Migration in last decade to high-risk prostate cancer after radical prostatectomy.
Prog Urol. 2018 Oct 15. pii: S1166-7087(18)30557-8. doi: 10.1016/j.purol.2018.09.008. [Epub ahead of print]
Source | Full text | Similar articles



bottom